Streetbeat News

Products Services

SOPH

SOPHiA GENETICS (NASDAQ:SOPH) has announced a new Residual Acute Myeloid (RAM) Application to monitor Acute Myeloid Leukemia (AML). This new tool expands their oncology portfolio and will be available globally this summer.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:21 am

ALC

Alcon (NYSE:ALC) has received FDA 510(k) clearance for its UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS). These systems are part of Alcon's new Unity portfolio and are expected to bring significant workflow efficiencies and technological advancements in cataract and vitreoretinal surgeries. The company plans to begin commercial launch in 2025 after securing real-world feedback and further regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:19 am

NVO

Novo Nordisk's obesity medication, Wegovy, has shown greater weight loss in women with heart disease compared to men. The study data was presented at the American Diabetes Association’s scientific meeting. The Centers for Medicare and Medicaid Services (CMS) is reviewing the inclusion of Wegovy in its coverage for heart disease patients with obesity. Goldman Sachs analysts have re-rated Novo Nordisk, expecting significant growth in the weight-loss drug market.

Portfolio Pulse from Benzinga Neuro

June 24, 2024 | 7:17 am

GUTS

Fractyl Health, Inc. (NASDAQ:GUTS) presented new preclinical data on its Rejuva pancreatic gene therapy program for obesity and type 2 diabetes at the American Diabetes Association's 84th Scientific Sessions. The study showed promising results in maintaining body composition and glycemia in a mouse model after semaglutide withdrawal.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:12 am

TAK

Takeda's LIVTENCITY (maribavir) has received approval from the Japanese Ministry of Health, Labour and Welfare for treating post-transplant cytomegalovirus (CMV) infection/disease that is resistant to existing therapies. This marks the first approval in Japan for a post-transplant anti-CMV treatment targeting pUL97 kinase.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:10 am

META

SQ

Jack Dorsey, CEO of Block Inc. (NYSE:SQ) and co-founder of Twitter, warned about the future challenges of distinguishing reality from deepfakes. He emphasized the need for personal verification of information. Elon Musk responded by questioning if we are already living in a simulated reality. The rise of AI and deepfakes has raised concerns about misinformation, with companies like Meta Platforms Inc. (META) addressing AI-generated fake news.

Portfolio Pulse from Ananya Gairola

June 24, 2024 | 7:09 am

TAK

Takeda (TAK) presented positive Phase 2b trial results for mezagitamab (TAK-079) in treating primary immune thrombocytopenia (ITP). The study showed significant improvements in platelet response and reduced bleeding events. Takeda plans to initiate a global Phase 3 trial in FY2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:09 am

NRBO

NeuroBo Pharmaceuticals (NASDAQ:NRBO) announced pre-clinical data showing that its novel drug DA-1726 is superior in weight loss, lean body mass retention, and lipid-lowering effects compared to survodutide. The data will be presented at the ADA 2024 Scientific Sessions.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:06 am

MNKD

MannKind Corporation (NASDAQ:MNKD) announced positive 17-week results from the INHALE-3 study, a Phase 4 U.S. clinical trial evaluating Afrezza® (inhaled insulin) vs. usual care. The study met its primary efficacy endpoint, showing non-inferior changes in HbA1c and better glycemic target achievement in the inhaled insulin group.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 7:04 am

TERN

Terns Pharmaceuticals (NASDAQ:TERN) announced preclinical data for its obesity treatment, TERN-501, which will be presented at the ADA 2024 Scientific Sessions. The data highlights the combination of TERN-501, a THR-β receptor agonist, with a GLP-1 receptor agonist.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 6:59 am